Literature DB >> 29622654

Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma.

Serena Rocchi1, Paola Tacchetti1, Lucia Pantani1, Katia Mancuso1, Beatrice Zannetti1, Michele Cavo2, Elena Zamagni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29622654      PMCID： PMC6058770          DOI： 10.3324/haematol.2018.191122

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Authors:  Antonio Palumbo; Asher Chanan-Khan; Katja Weisel; Ajay K Nooka; Tamas Masszi; Meral Beksac; Ivan Spicka; Vania Hungria; Markus Munder; Maria V Mateos; Tomer M Mark; Ming Qi; Jordan Schecter; Himal Amin; Xiang Qin; William Deraedt; Tahamtan Ahmadi; Andrew Spencer; Pieter Sonneveld
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

2.  Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.

Authors:  Arjun Lakshman; Jithma P Abeykoon; Shaji K Kumar; S Vincent Rajkumar; David Dingli; Francis K Buadi; Wilson I Gonsalves; Nelson Leung; Angela Dispenzieri; Taxiarchis V Kourelis; Ronald S Go; Martha Q Lacy; Miriam A Hobbs; Yi Lin; Rahma Warsame; John Lust; Amie L Fonder; Yi L Hwa; Suzanne R Hayman; Stephen J Russell; Robert A Kyle; Morie A Gertz; Prashant Kapoor
Journal:  Am J Hematol       Date:  2017-09-08       Impact factor: 10.047

3.  Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.

Authors:  Meletios Dimopoulos; Katja Weisel; Niels W C J van de Donk; Karthik Ramasamy; Barbara Gamberi; Matthew Streetly; Massimo Offidani; Frank Bridoux; Javier de la Rubia; Maria-Victoria Mateos; Antonio Ardizzoia; Elisabeth Kueenburg; Shona Collins; Antonia Di Micco; Barbara Rosettani; Yan Li; Pamela Bacon; Pieter Sonneveld
Journal:  J Clin Oncol       Date:  2018-02-02       Impact factor: 44.544

4.  Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Authors:  Sagar Lonial; Brendan M Weiss; Saad Z Usmani; Seema Singhal; Ajai Chari; Nizar J Bahlis; Andrew Belch; Amrita Krishnan; Robert A Vescio; Maria Victoria Mateos; Amitabha Mazumder; Robert Z Orlowski; Heather J Sutherland; Joan Bladé; Emma C Scott; Albert Oriol; Jesus Berdeja; Mecide Gharibo; Don A Stevens; Richard LeBlanc; Michael Sebag; Natalie Callander; Andrzej Jakubowiak; Darrell White; Javier de la Rubia; Paul G Richardson; Steen Lisby; Huaibao Feng; Clarissa M Uhlar; Imran Khan; Tahamtan Ahmadi; Peter M Voorhees
Journal:  Lancet       Date:  2016-01-07       Impact factor: 79.321

5.  Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Authors:  Henk M Lokhorst; Torben Plesner; Jacob P Laubach; Hareth Nahi; Peter Gimsing; Markus Hansson; Monique C Minnema; Ulrik Lassen; Jakub Krejcik; Antonio Palumbo; Niels W C J van de Donk; Tahamtan Ahmadi; Imran Khan; Clarissa M Uhlar; Jianping Wang; A Kate Sasser; Nedjad Losic; Steen Lisby; Linda Basse; Nikolai Brun; Paul G Richardson
Journal:  N Engl J Med       Date:  2015-08-26       Impact factor: 91.245

Review 6.  Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Authors:  Philippe Moreau; Niels W C J van de Donk; Jesus San Miguel; Henk Lokhorst; Hareth Nahi; Dina Ben-Yehuda; Michele Cavo; Gordon Cook; Michel Delforge; Hermann Einsele; Sonja Zweegman; Heinz Ludwig; Christoph Driessen; Antonio Palumbo; Thierry Facon; Torben Plesner; Meletios Dimopoulos; Pia Sondergeld; Pieter Sonneveld; María-Victoria Mateos
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

7.  Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

Authors:  Jakub Krejcik; Tineke Casneuf; Inger S Nijhof; Bie Verbist; Jaime Bald; Torben Plesner; Khaja Syed; Kevin Liu; Niels W C J van de Donk; Brendan M Weiss; Tahamtan Ahmadi; Henk M Lokhorst; Tuna Mutis; A Kate Sasser
Journal:  Blood       Date:  2016-05-24       Impact factor: 22.113

Review 8.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors:  Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316

9.  Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Authors:  Saad Z Usmani; Brendan M Weiss; Torben Plesner; Nizar J Bahlis; Andrew Belch; Sagar Lonial; Henk M Lokhorst; Peter M Voorhees; Paul G Richardson; Ajai Chari; A Kate Sasser; Amy Axel; Huaibao Feng; Clarissa M Uhlar; Jianping Wang; Imran Khan; Tahamtan Ahmadi; Hareth Nahi
Journal:  Blood       Date:  2016-05-23       Impact factor: 22.113

10.  Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.

Authors:  Jesus Berdeja; Sundar Jagannath; Jeffrey Zonder; Ashraf Badros; Jonathan L Kaufman; Robert Manges; Manish Gupta; Amol Tendolkar; Mark Lynch; Eric Bleickardt; Prashni Paliwal; Ravi Vij
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-12-21
View more
  9 in total

1.  Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure.

Authors:  Elizabeth Smyth; Siobhan Glavey; Dario Melotti; Patrick Thornton; Jeremy Sargent; Peter Conlon; Philip Murphy; John Quinn
Journal:  Ir J Med Sci       Date:  2018-12-19       Impact factor: 1.568

2.  Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.

Authors:  Shinichi Mizuno; Chigusa Kitayama; Shigeto Mashiko; Satoru Sanada
Journal:  CEN Case Rep       Date:  2021-11-24

3.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.

Authors:  Nina Shah; Jack Aiello; David E Avigan; Jesus G Berdeja; Ivan M Borrello; Ajai Chari; Adam D Cohen; Karthik Ganapathi; Lissa Gray; Damian Green; Amrita Krishnan; Yi Lin; Elisabet Manasanch; Nikhil C Munshi; Ajay K Nooka; Aaron P Rapoport; Eric L Smith; Ravi Vij; Madhav Dhodapkar
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

4.  Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists.

Authors:  Catarina Geraldes; Manuel Neves; Sérgio Chacim; Fernando Leal da Costa
Journal:  Front Oncol       Date:  2022-02-04       Impact factor: 6.244

5.  Speckle Noise Algorithm-Based Ultrasound Imaging in Evaluating the Therapeutic Effect of Blood Purification on Children with Kidney Failure and Analysis of Its Correlation with Serum Inflammatory Factor Levels.

Authors:  Xueqin Li; Hui Guo; Soinam Songjin; Ning Mo; Xiuying Chen
Journal:  J Healthc Eng       Date:  2022-01-29       Impact factor: 2.682

Review 6.  An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.

Authors:  Meletios A Dimopoulos; Joseph Mikhael; Evangelos Terpos; Xavier Leleu; Philippe Moreau; Joan Bladé; Jin Seok Kim; Keith Stockerl-Goldstein; Paul G Richardson
Journal:  Ther Adv Hematol       Date:  2022-04-02

7.  Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.

Authors:  Marcelo Capra; Thomas Martin; Philippe Moreau; Ross Baker; Ludek Pour; Chang-Ki Min; Xavier Leleu; Mohamad Mohty; Marta Reinoso Segura; Mehmet Turgut; Richard LeBlanc; Marie-Laure Risse; Laure Malinge; Sandrine Schwab; Meletios Dimopoulos
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

8.  Daratumumab in dialysis-dependent multiple myeloma.

Authors:  Preethi Jeyaraman; Alka Bhasin; Nitin Dayal; Sangeeta Pathak; Rahul Naithani
Journal:  Blood Res       Date:  2020-03-30

9.  Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.

Authors:  Masuho Saburi; Masao Ogata; Yasuhiro Soga; Yoshiyuki Kondo; Ryo Kurimoto; Kazuhito Itani; Kazuhiro Kohno; Hiroki Uchida; Toshiyuki Nakayama
Journal:  J Clin Exp Hematop       Date:  2020
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.